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Herpes simplex virus 1 (HSV-1) infection of the cornea leads to a potentially blinding disease, termed herpetic stromal keratitis
(HSK) that is characterized by lesions of an immunoinﬂammatory nature. In spite of the fact that HSK typically presents as a
recurrent disease due to reactivation of virus which latently infects the trigeminal ganglia, most murine studies of HSK have
employed a primary and not recurrent model of the disease. This report documents the several recurrent models of HSK that
have been developed and how data generated from these models diﬀers in some important aspects from data generated following
primaryinfectionofthecornea.ChiefamongthesediﬀerencesisthefactthatrecurrentHSKtakesplaceinthecontextofananimal
that has a preexisting anti-HSV immune response, while primary HSK occurs in an animal that is developing such a response. We
will document both diﬀerences and similarities that derive from this fundamental diﬀerence in these models with an eye towards
possible vaccines and therapies that demonstrate promise in treating HSK.
1. Opening Comments
Herpetic stromal keratitis (HSK) is a potentially blinding
cornealinﬂammationthataccompaniesherpessimplexvirus
type 1 (HSV-1) infection of the eye. The disease course in
HSK begins with a primary infection by HSV followed by a
period during which the virus enters latency in sensory and
autonomic ganglia. Many studies have shown that clinical
disease is the result of a cocktail of inﬂammatory cells, con-
sisting of PMN’s, macrophages, and T cells (both CD4+ and
CD8+) that are recruited to the corneas of patients with HSK
[1–4].
Most animal studies of HSK have focused on primary
ocular infection. The major drawback with extrapolating
data from primary HSV infection in mice is that it often does
notmanifestcorneallesionscharacteristicofhumanprimary
or recurrent HSK [5]. We believe that there are four advan-
tages in using a recurrent model of HSK. The ﬁrst is that
recurrent human disease is most often associated with
corneal scarring [6, 7]. Second, the clinical proﬁle in the
murine recurrent model mimics many of the symptoms
observed in human disease [8]. Namely, that primary infec-
tion resulted in multiple epithelial dendrites, followed by
diﬀuse stromal opaciﬁcation, while recurrent infection pre-
sented clinical features that included microdendrites, focal
stromal opacities, disciform endotheliitis, and corneal neo-
vascularization, which were more similar to those observed
in human disease. Third, the model allows reactivation to
occur in the context of an immune host. This is also the
case in humans where disease takes place in a host that
has developed an adaptive immune response against HSV-1.
W h i l ei ti sn o ts u g g e s t e dt h a ts u c ha d a p t i v er e s p o n s e sw i l l
be identical, they will likely be more similar than extending
what occurs following primary infection, where an adaptive
response is initially developing (most murine studies),
to what is taking place in an “immune host” following
reactivation. Finally, a recurrent model lends itself to testing
the eﬃcacy of HSV vaccines. Since human disease typically
occurs following reactivation, identifying vaccines that are
eﬀective when used therapeutically would be very valuable2 Clinical and Developmental Immunology
and a recurrent model allows for that evaluation. This is
criticalasmanyvaccineswhichshoweﬃcacyinprimaryHSK
models fail when tested in a reactivation paradigm [9].
T h e r ea r es e v e r a ld i ﬀerent protocols that have been used
toreactivatemicefromlatency.Oneoftheﬁrstmethodsused
to reactivate mice latently infected was treating mice with
the immunosuppressive drug cyclophosphamide (CycloP)
[10]. Later Shimeld et al. developed a model in which mice
are infected with the McKrae strain of HSV-1 and given
passive immunization in the form of pooled serum. The
eyes of these latently infected mice are exposed to UV-B
irradiation at least 30 days following primary infection to
induce reactivation [11–14]. The reason for the addition of
passive immunization is that this reduced the high incidence
ofmortalityandalsopreventedacuteHSK,whichwouldlead
to permanent corneal damage [13]. It was also noted that the
latent infection was restricted to the ophthalmic part of the
trigeminal ganglia [13]. When Shimeld et al. [12] and later
Laycock et al. [14] compared UV-B irradiation to CycloP
+ dexamethasone, the incidence of virus shedding from the
cornea was greater for the UV-B-treated mice and recurrent




various strains of mice have been tested for their ability to
reactivate following UV-B irradiation and the NIH strain
of mice consistently displays the highest rate of reactivation
(70–90%) as determined by detection of infectious virus in
tearﬁlm[9,14,15].Inaddition,severityofdiseasealsovaries
between diﬀerent mouse strains with NIH and BALB/c mice
showing severe disease and C57BL/6 mice with much less
disease [9, 15, 16]. Other investigators have also developed
other means of reactivating a latent HSV-1 infection by
usinghyperthermiashock[17,18]andmostrecentlysodium
butyrate [19]. The hyperthermia shock model is used to
determine reactivation within the infected ganglion neurons
and thus is a very good model to study molecular events that
occur there following reactivating stress [17, 18]. However it
has not been exploited to study corneal disease. The sodium
butyrate model, which does result in viral shedding from the
corneal surface [19], has also not been exploited to study
corneal disease. Thus, while each of these techniques has
their own distinct advantages and disadvantages, the UV-B
model has been used much more extensively for pathogenic
and immunological studies of recurrent HSK. Thus this
paper will restrict itself to the reactivation model whereby
UV-B light is used to reactivate virus from latency. This was
chosen as the vast majority of data concerning the pathogen-
esis of recurrent disease has used that model.
As a basis for comparison, a few factors should be
mentioned. The ﬁrst being that diﬀerent investigators use
a variety of strains of HSV-1 when studying primary HSK.
The virus strains that have been used for these studies
i n c l u d e ,b u ta r en o tr e s t r i c t e dt o ,R E[ 4, 20, 21], Strain
17 [19], McKrae [8, 15, 22], CH394 [23], and KOS [15,
24]. In addition to a variety of HSV-1 strains being used,
various mouse strains have also been used for these studies.
Most studies employ C57BL/6 or BALB/c mouse strains or
gene-targeted mice that are bred to these two strains. It
should be noted that while infections with these various
strains ofHSV-1display diﬀerencesin cornealpathology and
neurovirulence, the immunological components of corneal
disease are remarkably similar when compared on the basis
of virus strain used or the strain of mouse being infected as
the following discussion will illustrate.
2.CharacteristicsofHerpeticStromalKeratitis
As previously mentioned, HSK is at its core an inﬂammatory
disease with chemokines involved in migration of leukocytes
to sites of infection and inﬂammation [25, 26] and cytokines
responsible for the activation of cells which mediate the cel-
lular destruction following their activation. Primary models
have shown that during disease, a diverse set of host inﬂam-
matory cells inﬁltrate the cornea following HSV-1 infection.
Included among these cells are macrophages [8, 9], natural
killer cells [27], T cells [8, 20, 28–33], polymorphonuclear
neutrophils (PMNs), which are the predominant cell type
early during primary infection with HSV-1 [34, 35], and
corneal Langerhans Cells [36]. While the exact mechanism
for primary HSK has not been conclusively determined, the
disease is believed to be the result of the interaction of virus
andhostimmunecellsandcomponentsandnotduetodirect
viral cytolysis of corneal cells [23]. Since much fewer studies
haveemployedtherecurrentmodel,evenlessisknownabout
the mechanisms responsible for recurrent HSK.
3. Role of Chemokines in HSK
Chemokines are important factors in viral infections [37]
and HSK [21, 38–40]. These are small proteins which are
made by resident tissue cells and/or immunocompetent cells
and whose primary function is to direct the movement or
chemotaxisofcellsthatbearreceptorsforthechemokinethat
is being produced. Thus during infection chemokines are
released by cells at the site of infection to activate the
migration of particular cells bearing appropriate chemokine
receptors to that site of infection. Chemokines have also
been implicated in activation and polarization of certain
immunocompetent cells [41]. Due to these activities, they
are potential targets for therapeutic intervention to reduce
or prevent disease (see Table 1 for cells responsive to chemo-
kines and references related to HSK). During primary HSK
it has been shown that the production of IL-6 stimulates
resident corneal cells to produce CCL3 and CXCL2 [42].
Studies have shown that targeting of CCL3 signiﬁcantly
reduces disease [39, 43], suggesting that it plays a role in
corneal pathology during primary HSK. In contrast, when
CCL3 is neutralized or absent during recurrent HSK, the
resulting disease is worse [40]. Likewise, targeting CCL2
reduced primary [44–46] but did not aﬀect recurrent disease
[40]. Eo et al. [45] coimmunized mice with a plasmid
encoding gB of HSV along with various plasmids containing
CCL1, CCL3, CCL4, and CXCL2, which are known to be
produced by the cornea [42, 45, 47], to determine if the
adaptive immune response generated was aﬀected by theClinical and Developmental Immunology 3
Table 1
Chemokine Chemotactic
activity Reference to HSK
CCL1 (Kit ligand) Monocytes,
NK cells, DC [45]
CCL2 (MCP-1) Monocytes, T
cells, DC [40, 44–46]








CXCL1 (KC) Neutrophils [47, 49]






presence of speciﬁc chemokines. Their data indicates that
the chemokines CCL1 and CCL4 biased immunity to a
Th2-like response, while CXCL2 and CCL3 activated a Th1
response. Mikloska et al. observed increased levels of CCL4
and, to a lesser extent, CCL3 and CCL5 in human vesicle
ﬂuid from patients with herpetic corneal lesions [48].
Similar studies evaluating CXCL1 expression have shown
that infection of corneal-derived cells with HSV-1 leads to
signiﬁcant increases in CXCL1 production, which stimulates
neutrophil chemotaxis [47, 49]. It has been reported that
CXCL10 is very important in recruiting activated T cells
into sites of inﬂammation [50]. However, CXCL10 has been
shown to be a mediator of IL-12-mediated antiangiogenesis
during primary HSK [51, 52]. Thus it is possible that
CXCL10 might be involved in both promoting disease, by
attracting activated CD4+ T cells, and in preventing disease
by inhibiting corneal angiogenesis. The role of murine
CXCL1, CXCL10, and IL-6 play during recurrent HSK has
not been determined; however, they are currently being
investigated in our laboratory at this time.
4.CytokineProﬁle ExpressedduringHSK
In addition to chemokines, HSK is also the result of the
action of various cytokines. Some of these cytokines (IL-1,
IL-6, IL-17, and TNFα) are found early following virus
infection [38, 53–55] and some (IL-1 and TNFα)f o u n d
shortly after reactivation [56]. Staats and Lausch detected
increased levels for proinﬂammatory cytokines, IL-1α,a n d
IL-6 following primary HSV-1 infection [53]. In addition,
targeting IL-1 during primary HSV-1 signiﬁcantly reduced
disease indicating its central role following acute infection
[54]. During recurrent HSK our laboratory also detected sig-
niﬁcantincreasesinbothIL-1,andTNFα[56].Furthermore,
when these cytokines were neutralized in vivo, they were
shown to be required for the development of recurrent HSK
[56].
Following this proinﬂammatory period, a somewhat
overlapping set of cytokines (IFN-γ, IL-12, IL-17, IL-4 and
IL-10) are found later during primary HSK [38, 53, 54, 57,
58], while during this same time period recurrent HSK the
cytokines IFN-γ,I L - 1 2 ,I L - 4 ,a n dI L - 1 0a r er e p o r t e dt ob e
expressed [59–61]. These cytokines can be very informative
as they will be indicative of the phenotype of the T cell
that is orchestrating the response at that time point. The
proﬁle of cytokines made by antigen-speciﬁc T cells in an
immune response indicates whether it is mediated by Th1,
Th2, or Th17 T cells. A Th1 response is characterized by
the production of IL-2, IL-12, and IFN-γ [62], Th2 cells
produce IL-4, IL-5, IL-6, and IL-10 [62], while Th17 cells
produce IL-17A, IL-17F, and IL-22 [63]. It has been reported
that signiﬁcant levels of IFN-γ,I L - 2 ,a n dT N F - α/β,b u tn o t
IL-4 or IL-10, are found in mouse corneas with primary
HSK, suggesting that CD4+ T cells in the eye are Th1 [31].
Similarconclusionswerederivedfromstudiesdemonstrating
that treatment with anti-IFN-γ and anti-IL-2 antibodies, but
not with anti-IL-4 antibodies, protected mice from primary
HSK [64]. It has been reported that IL-2 not only stimulates
Th1 development but also is chemotactic for and maintains
the viability of polymorphonuclear neutrophils [65], which
are an early component of primary HSK [34, 35]. Further
evidence supporting Th1 cell involvement comes from
studies using STAT4 KO mice [66]. STAT4 is a transcription
factor that is activated by the presence of IL-12 and directs
the polarization of T cells to become Th1 cells [67, 68].
When infected with HSV-1, these STAT4 KO mice did not
develop signiﬁcant primary HSK lesions, though they were
more susceptible to developing encephalitis [66]. In contrast
to these results, it has been shown that when IFN-γ KO mice
wereusedtoconﬁrmtheroleofthiscytokineduringprimary
HSK surprisingly displayed similar disease to that seen in
wild-type mice [67]. This was surprising as one would have
expected that such mice would display less corneal disease as
IFN-γ is an integral cytokine associated with Th1 responses
[62,68].Interestingly,averysimilarphenotypewasobserved
in mice undergoing recurrent HSK [69]. In these studies
both IFN-γ KO mice and wild-type mice treated with anti-
IFN-γ were subjected to recurrent HSK and the disease was
indistinguishable from recurrent HSK in control antibody-
treated wild-type mice [69].
In a completely diﬀerent set of studies to determine the
role of IL-10 during HSK, it was reported that intraocular
treatment of mice with IL-10 reduced corneal disease from
95% to 36% [43, 70]. This treatment, while not eﬀecting the
production of IL-1α in the cornea, led to a 10-fold reduction
i nI L - 2a n da5 0 - f o l dr e d u c t i o ni nI L - 6[ 70]. It has also been
reported that IL-10 DNA administration during primary
HSK signiﬁcantly reduced disease [71]. Our laboratory also
evaluatedtherolethatIL-10playsduringrecurrentHSK,and
similar to what was reported during primary HSK [43, 70],
lack of IL-10, as determined by neutralizing IL-10 or using
IL-10 KO mice, resulted in very severe corneal disease [72].
Furthermore, treating mice with recombinant IL-10 led to
signiﬁcantly reduced corneal disease [72]. Taken together,
these studies, both in primary HSK and recurrent HSK,4 Clinical and Developmental Immunology




Th17 because of their production of the cytokine IL-17 [63].
They have been shown to be involved in autoimmunity and
host defense [63]. It was ﬁrst reported that mice lacking IL-
17 receptor displayed reduced neutrophil inﬁltrate and less
corneal disease [73]. This observation was followed by a
report that showed that treatment with Resolvin E1 reduced
clinical disease and at the same time reduced the numbers
of both Th1 and Th17 cells in the cornea [74], further
indicating that Th17 cells might be playing a role in primary
HSK. That role was further supported when IL-17 KO mice
and wild type mice treated with neutralizing antibodies
were infected with HSV-1. These studies demonstrated that
primary HSK was signiﬁcantly inhibited thus indicating that
both Th1 and Th17 cells likely act in concert to produce the
corneal lesions seen during primary HSK [54]. The role that
Th17 cells, and thus the cytokine IL-17, play in recurrent
HSK has yet to be evaluated.
5.T-CellFunctionsduringHSK
As the aforementioned research implies, T cells are critical to
the development of corneal lesions during both primary and
recurrent HSK. In fact, T-cell deﬁcient mice do experience
HSK [28], unless T cells are adoptively transferred [29].
During primary HSK, the preponderance of data suggests
thatCD4+ TcellsoftheTh1subsetarethelikelymediatorsof
disease [30, 31, 64, 70, 71] while CD8+ T cells play a minor
role in disease [22, 30, 31, 33, 75] or possibly are involved
in reducing disease [15]. Studies attempting to determine if
the classical CD4+ FoxP3+ Treg cells are involved in reducing
corneal disease have not conclusively demonstrated that they
do so in vivo [4]. Another means of determining the func-
tional role of T cells is the measurement of DTH responses,
which are most often mediated by the Th1 subset of
CD4+ T cells. Using this readout, decreased disease is most
often associated with reduced DTH responses [76, 77],
though in one case where both Th1 and Th2 responses
were allowed to develop, HSK was reduced, but DTH was
unaltered [78]. During recurrent HSK, the T-cell proﬁle
is somewhat diﬀerent. Whether by targeting these T-cell
subsets by antibody depletion or by using CD4KO and
CD8KO mice, these mice expressed a decreased HSK disease
phenotype as compared to wild-type and untreated mice
[79]. Thus it would appear that both CD4+ and CD8+ Tc e l l s
contribute to clinical disease during recurrent HSK [79]. In
addition, when the cytokine pattern was investigated, both
Th1 and Th2 cytokines were present in the cornea shortly
following reactivation [60]. These results should not be
surprising as it should be recalled that recurrent HSK occurs
in mice that have developed an immune response against
HSV-1. That immune response will include antigen-speciﬁc
CD4+ T cells of both Th1 and Th2 subsets as well as HSV-1-
speciﬁc CD8+ T cells. Thus the mixed T-cell inﬁltrate may, at
least in part, explain why focal stromal opacities, rather than
the diﬀuse opacity, as typically seen in primary HSK, char-
acterize recurrent HSK in mice [8]. That said, while there is
a report implicating cytotoxic T cells in primary disease [80],
recurrent disease is most often associated with strong DTH
responses [72, 81].
Since T cells clearly play a central role in mediating
disease, identifying those factors that are involved in their
activation is very important. A critical factor for activation
of T cells is the engagement of costimulatory molecules.
Thebestcharacterizedofthesecostimulatoryinteractionsare
between CD28 or CTLA-4 on the T cell and B7-1 or B7-2
expressed by the APC [82]. Studies have shown that blocking
the CD28 interaction with CTLA-4Ig signiﬁcantly reduced
primary HSK by inhibiting Th1 but not Th2 cells [83]. When
only B7-2 was blocked, there was a signiﬁcant reduction in
CD8+ cytotoxic T-cell response and these mice experienced
delayed viral clearance at the cornea [84]. However, these
treated mice did not display an impact on corneal disease,
suggesting that na¨ ıve CD4+ T cells are being costimulated
via B7-1 [84]. The Hendricks laboratory demonstrated that
targeting the CD40-CD154 interaction changed the cellular
nature of the inﬂammatory response but did not result
in reduced primary HSK [85], while targeting the OX40-
OX40L interaction did not signiﬁcantly alter primary HSK
in any way [86]. When the CD137-CD137L costimulatory
pathway was targeted, reduced primary HSK was observed
[87]. However, it is interesting to note that this same group
later demonstrated that this interaction led to increased
CD8+ T-cellresponsesthatbettercontrolledHSV-1infection
of the skin [88]. We are currently addressing the role that
costimulation plays in recurrent HSK. We hypothesize that
since recurrent HSK occurs in an animal that possesses
an anti-HSV-1 immune response, we believe that CD28-
mediated costimulation will primarily be associated with the
initial T-cell activation that occurs shortly after infection and
likelyisnotinvolvedinsubsequentstimulationofpreexisting
anti-HSV-1 T cells that will be present when reactivation of
virus from latency occurs. However, it is possible that other
costimulatory interactions that occur subsequent to CD28
activation might be important in recurrent HSK. It will be
those interactions (CD40-CD154 and CD137-CD137L) that
are the focus of ongoing studies in our laboratory.
6.Role ofTCellsinMaintainingViralLatency
In addition to their role in mediating corneal disease, T cells
have also been implicated in maintaining viral latency in the
infected trigeminal ganglia (TG). This role for T cells comes
primarily from work done in the laboratory of Robert
Hendricks, whoreported thatCD8+ T cells surroundlatently
infectedTGneuronsinmiceinfectedwithHSV-1[89–92].In
a similar fashion, clinical studies performed on recently de-
ceased individual who know to have infections with HSV-
1, found both CD8+ and CD4+ T cells surrounding neurons
that are also stained for HSV-1 antigens [93, 94]. These
cells expressed surface markers indicating that they were late
eﬀector memory T cells. As was seen in mice, they expressed
granzyme markers but no cytolytic function was detectedClinical and Developmental Immunology 5
[94]. It has since been reported in murine studies that the
production of IFNγ,g r a n z y m e ,a n dp e r f o r i nb yTc e l l si s
important to this maintenance of latency [95, 96]. It was
further shown that these infected neurons were not under-
going apoptosis, but that the target of granzyme B released
by T cells was the HSV-1 immediate early protein, ICP4 [95],
which is essential for further viral gene expression and thus
production of infectious virus [97]. More recently the TCR
usage of these T cells found in latently infected C57BL/6 TG
wascharacterized[98].Itwasdemonstratedthatthemajority
were speciﬁc for a glycoprotein B peptide, but that CD8+ T
cells speciﬁc for at least 18 other subdominant determinants
could be found [98]. One caveat to these studies is that mice
lacking CD8+ T cells display a similar latency phenotype
as normal mice [14]. None the less, taken together, these
observations indicate that CD8+ T cells are likely involved in
maintaining latency but that other factors are also involved.
7. VaccinationinHSK
Many attempts have been made to develop a vaccine that
is eﬀective in preventing HSK. While most vaccines prevent
primaryHSKinanimalmodelswhengivenpriortoinfection
[99–103], they typically fail when delivered therapeutically
to prevent recurrent HSK [9, 104]. Nesburn et al. reported
that periocular vaccination of latently infected rabbits with
recombinantHSV-2gB/gDinMTP-PEadjuvantresultedina
2-3-fold decrease in spontaneous corneal viral shedding but
had no eﬀect on corneal scarring [105]. They also reported
that periocular vaccination with gD1 or gD2 inhibited
recurrent dendritic keratitis [106]. Likewise, we and others
haveshownthatvaccinationwithcertainHSV-1components
limits both viral pathogenesis and prevents primary and
recurrent corneal disease only when administered prior to
infection [9, 104]. If administered following infection these
vaccines are ineﬀective in preventing recurrent disease [9].
These studies illustrate the diﬃculty of developing eﬀective
vaccines for both primary and recurrent infections of HSV.
The development of such a vaccine would be of great clinical
signiﬁcance since most patients who present with HSK are
latently infected [1, 6, 7]. This was illustrated by a clinical
trial in which the vaccine was only eﬀective in women
who had never been infected with either HSV-1 or HSV-2
and ineﬀective in those who had a history of infections
with either HSV-1 or HSV-2 [107]. That said, we reported
that vaccination with a vhs-defective mutant of HSV-1
[108], which had previously been shown to signiﬁcantly
reduce the rate of reactivation [103, 104], would also reduce
recurrent HSK when constructed with [109] or without
ICP8 [81]. The important thing about these studies was
that the vaccine was administered intraperitoneally after
infection and thus would have therapeutic value for latently
infected individuals. It should be noted that another vaccine
construct that consisted of defective vhs and ICP8 to which
was cloned B7-1 or B7-2 was also eﬀective prophylactically
[110]andmightalsoshoweﬃcacywhenusedtherapeutically
since it is very similar to previous vaccine constructs [81,
109]. Similar results were also seen in studies by Richards
et al. who nasally vaccinated latently infected mice with a
mixture of HSV-1 glycoproteins and recombinant E. coli
heat-labile enterotoxin B subunit as an adjuvant [111].
Themechanismresponsibleforthetherapeuticsuccessof
these vaccine constructs has not been fully deﬁned. However,
the mechanism could be similar to what was reported
in studies involving Theiler’s virus- (TMEV-) mediated
demyelinating disease in mice. This disease, which is asso-
ciated with a Th1 antiviral response, was shown to be signif-
icantly reduced in infected mice following vaccination with
TMEV-coupled spleen cells [112, 113]. These investigators
went on to demonstrate that protection is accompanied by
a preferential reduction in the Th1 antiviral response and a
concomitantincreaseintheTh2-mediated antiviralresponse
[113]. Thus it appears that protection involves alteration of a
Th1-mediated immune response to one primarily mediated
by Th2 cells. Results from our vaccination studies using a vhs
defective replication incompetent virus show similar changes
as evidenced by lower DTH responses and increased anti-
HSV-1 neutralizing antibody titers in vaccinated mice as
compared to mice receiving a control vaccine [81]. Ocular
HSV-1 infection typically stimulates an immune response
that protects the animal from lethal disease by this virus
but also leads to a signiﬁcant inﬂammatory response in the
cornea that can result in corneal damage. A similar type
of immune response also protects latently infected animals
that are reactivated from lethal viral disease but can result
in signiﬁcant corneal disease. The mechanism underlying
this alteration in the immune response might involve the
activation of T regulatory cells. Both conventional CD4+ T
cells [114, 115] and CD8+ T cells [15] have been implicated
in regulating the anti-HSV-1 response during primary HSK.
However, when Devito and Hendricks tested this, they did
not observe an association for T regulatory cells within the
cornea and decreased corneal lesions [4]. Thus the case for
T regulatory involvement in reducing or resolving primary
HSK remains to be established.
8. Concluding Remarks
Ocular disease associated with HSV-1 infection (HSK) is
the leading cause of infectious blindness and is clearly the
result of an immune-mediated inﬂammatory attack of the
cornea. We present data comparing primary and recurrent
murine models that are used to study this disease. As
should be evident from this discussion, these two model sys-
tems, while sharing many characteristics, are not the same.
We have learned a lot about this disease from studies of
primaryHSK.Thesestudieshaveidentiﬁedmanyfactorsthat
are responsible for the corneal damage associated with this
disease.Infact,thesestudieshavealsosuggestedmanypoten-
tialtherapeuticmeansoftreatingprimaryHSK.However,we
would argue that without testing these therapies in a recur-
rent model of HSK, we might be chasing things that ulti-
mately will not prove useful in the clinic. Consequently, due
to the paucity of studies investigating recurrent HSK, much
research remains to be performed. Particularly concerning
those aspects of primary HSK that are reﬂected in recurrent6 Clinical and Developmental Immunology
HSK and also those things that are not, we contend that
a better understanding of the immunological factors, both
cellular and cell-free, that underlie the development of re-
currentHSKwillenableustoidentifypotentialtherapiesthat
might prove to be most eﬀective in treating human HSK.
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